Work

Action of the anticancer drug cisplatin investigated by molecular simulation

Year: 2013
Type: dissertation
Abstract: Cancer is one of the leading causes of death worldwide. Among various chemotherapeutic drugs currently used in cancer treatment, cisplatin is one of the most important and successful drugs. It is the best hope for patients with testicular, ovarian and many other solid tumors. Cisplatin kills cancer cells by covalently binding to their DNA and causing DNA damages (cisplatin-DNA adducts). Albeit very efficient, cisplatin’s clinical utility is limited due to its toxic side effects and resistance. The mechanisms behind drug resistance are far from being completely understood. Experimental studies so far have suggested that binding of cisplatin to many cellular proteins is a key mechanism of drug resistance. In particular, the copper influx protein Ctr1 has been shown to be responsible for the decrease of cellular uptake of cisplatin, commonly found in resistant cells. Furthermore, even if cisplatin can successfully reach and bind to the DNA, cancer cells may be able to repair the cisplatin-DNA adducts by employing a number of proteins involved in the so-called Nucleotide Excision Repair (NER) pathway. This thesis has contributed to investigating processes, which are relevant to cisplatin resistance mechanism, using computational physics tools. (i) First, we have studied binding of cisplatin and transplatin (a pharmacologically inactive trans isomer of cisplatin) to a model peptide (called Mets7) that mimics one of the methionine(Met)-rich motifs of Ctr1. We have used a set of computational tools including QM/MM simulations, force matching technique, replica exchange MD simulations and computational spectroscopy to predict the structures of the adducts formed due to the binding of cisplatin and transplatin to Mets7. Comparison between calculated and experimental spectroscopic data such as NMR, EXAFS and CD allows us to validate our predicted structures and to propose the most relevant species in water solution. The structural models arising from our calculations may serve as the molecular basis for further attempts to understand cisplatin uptake mediated by Ctr1. (ii) Then, we have performed preliminary calculations on the interaction between cisplatin-DNA adduct and the High Mobility Group Box 1 (HMGB1) protein. HMGB1 (a DNA-binding protein) has been shown to be able to block the NER repair pathway by binding to the cisplatin-DNA adducts and shielding them from being repaired by NER proteins. Although experimental studies have shown the structural determinants of the cisplatin-DNA-HMGB1 complex and also provided the binding affinity, the mechanism of molecular recognition between cisplatin-DNA adduct and HMGB1 is still unknown. We aim at investigating structural and energetic insights of the binding of HMGB1 to the cisplatin-DNA adduct by applying free energy calculations based on metadynamics method. This thesis presents necessary calculations towards this goal.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: green
OpenAlex ID: W805379572
Cites: 281
Cited by: 1
Related to: 10